Drug delivery solutions
We are committed to investing in the next generation of excipients you need. Our teams work with you to troubleshoot formulations and develop research grade and GMP excipient solutions. Purity is our forte across our multi-compendial, GMP grade materials.
Explore by platform
We are a world leader of pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications. Explore our drug delivery platforms to learn more. We have a vast product offering available across each of our drug delivery platforms for human and veterinary applications, including Small Molecule Delivery, Protein Delivery, Nucleic Acid Delivery, Adjuvant Systems and Consumer Health.
Explore by product
We offer an extensive product offering to meet the needs for our customers. With an ever increasing list of high purity specialty ingredients, we are proud to be your partner in bringing drug products to market. Alongside our product range, we have extensive expertise in working with our products in their various applications, and actively work with customers to solve any issues they are facing, whether it be stabilising a difficult drug, delivering the drug to its intended site of action, or prolonging drug product shelf life through the use of high purity ingredients.
Explore by market
Our purpose, Smart science to improve lives™, is at the core of our human and veterinary market strategy. We support the pharmaceutical market by developing high purity excipients which enhance delivery, efficacy, and stability of actives. We also manufacture industry leading high purity vaccine adjuvants and innovative lipids.
Explore new products
Explore our newest range of products available across our technology platforms.
How we empower biologics delivery
Explore recent blogs:
Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4F9521E2A9CDAB872D1AA12B9BA9F4EB)
From Lab to Patient: Optimising Oncology Formulations with Purified Excipients
In 2024, we hosted a live webinar exploring the impact of our Super RefinedTM excipients on various chemotherapeutic formulations. This blog will explore some of the key learnings from the webinar.
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F330DFD631D5F6E81578038D37E005ED){kind=logo}
Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to...